Comparative Pharmacology
Head-to-head clinical analysis: DEXACEN 4 versus PREDNISOLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACEN 4 versus PREDNISOLONE.
DEXACEN-4 vs PREDNISOLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to increased transcription of anti-inflammatory proteins and suppression of pro-inflammatory mediators.
Prednisolone is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, inhibition of phospholipase A2, and reduction of prostaglandin and leukotriene synthesis.
Dexamethasone 4 mg orally or intravenously every 6-8 hours; typical adult dose is 4-20 mg/day in divided doses, depending on condition.
Initial adult dose: 5-60 mg orally, intramuscularly, or intravenously daily, divided into 2-4 doses; maintenance: 2.5-15 mg daily.
None Documented
None Documented
Clinical Note
moderatePrednisolone + Digoxin
"Prednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethylprednisolone + Digoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePrednisolone + Digitoxin
"Prednisolone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethylprednisolone + Digitoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digitoxin."
3-4 hours; prolonged to 6-8 hours in renal impairment (CrCl <30 mL/min)
Terminal half-life: 2.1-3.5 hours in adults; prolonged in hepatic impairment (up to 12 hours) or with concurrent estrogen use.
Renal: 65-80% as unchanged drug; Biliary: 10-15% as metabolites; Fecal: <5%
Renal (primarily as glucuronide and sulfate conjugates; <20% as unchanged prednisolone); biliary/fecal (minor, <5%).
Category C
Category D/X
Corticosteroid
Corticosteroid